ClinicalTrials.gg
RecruitingNCT07290777RENGEVITY-201Updated Sep 3, 2026

VEL-101 to Prevent Rejection After Kidney Transplantation

A Phase 2 interventional study of Tacrolimus (TAC) and VEL-101 in Transplantation, Kidney, sponsored by Veloxis Pharmaceuticals. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Veloxis Pharmaceuticals · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the safety and efficacy of VEL-101 compared with tacrolimus in patients undergoing kidney transplantation.

Read the detailed description

This study is a randomized, multicenter, partially blinded, active control study to evaluate the safety and effectiveness of VEL-101 compared with tacrolimus in the prevention of rejection in patients undergoing kidney transplantation. Up to 120 de novo kidney transplant recipients will receive rATG with corticosteroids (CS), and mycophenolate as maintenance therapy, and will be randomized 1:1:1 to receive either VEL-101 (low dose or high dose) or tacrolimus.

02

Conditions studied

  • Transplantation, Kidney

Keywords

  • Kidney transplant
  • VEL-101
  • pegrizeprument
  • renal allograft rejection
  • prophylaxis
  • kidney
  • renal
  • transplant
  • CD28 inhibitor
  • monoclonal antibody fragment
  • FR-104
  • Anti-CD28
03

In context

Lead sponsor

Veloxis Pharmaceuticals is the lead sponsor of 18 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Greater than or equal to 18 years of age
  2. Able to understand key components of the study as described in the written document and willing and able to provide written informed consent.
  3. If female, surgically sterile (post hysterectomy, bilateral salpingectomy, or bilateral oophorectomy), (greater than 12 months of amenorrhea without alternative medical causes), or, if of , is using a highly effective until 90 days after EOS visit.
  4. If male, is vasectomized, has undergone bilateral orchidectomy, agrees to abstinence of heterosexual intercourse, or only has female partner using highly effective contraception, surgically sterile or postmenopausal and agrees to use method until 90 days after EOS visit.
  5. Receiving kidney allograft from deceased donor or non-human leukocyte antigen (HLA) identical living donor.

    a) Repeat kidney transplant allowed if no previous kidney transplant(s) failed due to recurrent disease within first year, acute rejection or nonsurgical thrombosis

  6. Able \& willing to comply with all study procedures, including PK and PD assessments, as assessed by the Investigator
  7. Vaccination up to date per the center's SOC as assessed by the Investigator.
  8. In the opinion of the Investigator, is able to adhere to the study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Negative for EBV or Epstein-Barr nuclear antigen antibody
  2. Know allergy to study medication (rATG, , MMF, tacrolimus, or VEL-101) or its components or a history of a severe allergic reaction to any drug.
  3. History of previous non-kidney solid organ, vascular composite allograft, pancreatic islet, stem cell or bone marrow transplant.
  4. Planned multiorgan transplant, including dual or en-bloc kidney transplant
  5. Anticipated cold ischemia time (CIT) >30 hours
  6. Donor with Kidney Donor Profile Index (KDPI) > 85%
  7. Panel reactive antibody >80%, calculated panel-reactive antibody (CPRA)>80% or history of HLA desensitization
  8. Positive T or B cell flow, cytotoxic, or virtual crossmatch at Screening
  9. Current or historical DSA
  10. Recipient or donor with positive surface antigen (HBsAG), hepatitis B core antibody (HBcAb), hepatitis B virus (HBV) nucleic acid testing (NAT), virus (HCV) antibody, HCV NAT, (HIV), or HIV NAT
  11. Recipient who is CMV IgG negative (R-) receiving a kidney from a donor who is CMV IgG positive (D+)
  12. Thrombocytopenia ( \< 75,00/mm3), leukopenia (white blood cells [WBC] \<3,000/mm3), or anemia ( \<8 g/dL) at Screening
  13. History of inadequately treated active or latent mycobacterium tuberculosis (TB) infection
  14. abnormality on 12-lead (ECG) at Screening, as determined by the Investigator
  15. Positive pregnancy test or lactating at Screening with plans to continue lactating regimen throughout the study
  16. History of within the past 5 years (with the exception of non- basal or squamous cell carcinoma of the skin with successful treatment), or current active malignancy
  17. Liver disease, defined as having elevated (AST) and/or alanine aminotransferase (ALT) levels greater than three times the upper value of the normal range of the study center at Screening
  18. Medical condition requiring chronic use of daily prednisone doses >5 mg (or equivalent)
  19. End-stage renal disease caused by primary focal segmental glomerulosclerosis (FSGS), atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy, or monoclonal gammopathy of kidney significance

    a) Note: participants with an unknown cause of ESRD can be included.

  20. Participation in an study within 30 days or within 5 half-lives of the investigational agent, whichever is longer, prior to Screening
  21. Receiving any antibody or biologic medicinal product (with the exception of erythropoietin products) within 90 days prior to Screening
  22. Positive test for SARS-CoV-2 antigen, polymerase chain reaction (PCR), or equivalent testing, at Screening, if performed
  23. History or presence of coagulopathy, thrombophilia, unexplained bleeding or clotting disorders, or use of systemic anticoagulants at the time of transplant, with the exception of uremic coagulopathy or prophylactic heparin preparations.
  24. History or presence, upon clinical evaluation, of any illness or condition that, in the opinion of the Investigator, would interfere with the ability to provide or comply with study instructions, or that might confound the interpretation of the study results or put the participant at undue risk.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    VEL-101 Low Dose

    VEL-101 Low Dose

    Drug: VEL-101

  • Experimental
    VEL-101 High Dose

    VEL-101 High Dose

    Drug: VEL-101

  • Active comparator
    Tacrolimus

    Tacrolimus

    Drug: Tacrolimus (TAC)

Interventions

  • Tacrolimus Immediate Release in addition to SOC

  • VEL-101 in addition to SOC

    Also known as: Pegrizeprument, FR104

06

What researchers measure

Primary outcomes

  1. Incidence of serious adverse events (SAEs)

    Incidence of serious adverse events (SAEs)

    Time frame: Month 12

  2. Incidence of treatment emergent adverse events (TEAEs)

    Incidence of treatment emergent adverse events (TEAEs)

    Time frame: Month 12

  3. PK Parameter Cmax

    PK Parameter Cmax

    Time frame: Day 1, Month 3

  4. PK Parameter Cmin

    PK Parameter Cmin

    Time frame: Day 1, Month 3

  5. PK Parameter Tmax

    PK Parameter Tmax

    Time frame: Day 1, Month 3

  6. AUC from 0-8 hours

    AUC from 0-8 hours

    Time frame: Day 1, Month 3

  7. AUC from 0 to 48 hours

    AUC from 0 to 48 hours

    Time frame: Day 2

  8. VEL-101 Accumulation Ratio

    VEL-101 Accumulation Ratio

    Time frame: Month 3

  9. VEL-101 Pre-Dose Serum Concentration

    VEL-101 Pre-Dose Serum Concentration

    Time frame: Day 1, Day 14, Months 1, 2, 3, 6, 9, 12, Periprocedural (kidney biospy)

  10. Effect of Anti-Drug Antibody (ADA) Development on VEL-101 Serum Concentration

    Effect of Anti-Drug Antibody (ADA) Development on VEL-101 Serum Concentration

    Time frame: Months 1, 2, 3, 6, 9, 12, Periprocedural (kidney biopsy)

  11. Effect of Neutralizing Antibody (NAb) Development on VEL-101 Serum Concentration

    Effect of Neutralizing Antibody (NAb) Development on VEL-101 Serum Concentration

    Time frame: Day 1, Months 1, 2, 3, 6, 9, 12 and Periprocedural (kidney biopsy)

  12. VEL-101 CD28 Receptor Occupancy Concentration (%)

    VEL-101 CD28 Receptor Occupancy Concentration (%)

    Time frame: Days 1, 2, 3, 4, 5, 7, 14, 42, 70, 82, 91, 98 and Months 1, 2, 3, 6, 9, 12 and Periprocedural (kidney biopsy)

Secondary outcomes

  1. Percentage Participants Meeting Composite Endpoint

    Death, graft failure or biopsy proven acute rejection (BPAR, T cell mediated rejection \[TCMR\] Banff Grade \> or = to 1A or antibody-mediated rejection \[AMR\] )

    Time frame: Month 12

  2. Slope of estimated glomerular filtration rage (eGFR)

    Slope of estimated glomerular filtration rage (eGFR)

    Time frame: Month 12

  3. Incidence Injection Site Reaction

    Incidence Injection Site Reaction

    Time frame: Month 12

  4. Incidence Adverse Events of Special Interest (AESIs)

    AESIs Including BK viremia, BK virus-associate nephropathy, EBV viremia, PTLD, CMV viremia, CMV disease, malignancies

    Time frame: Month 12

  5. Proportion of Participants Discontinuing due to Adverse Events

    Proportion of Participants Discontinuing due to Adverse Events

    Time frame: Month 12

  6. Incidence Delayed Graft Function Delayed Graft Function

    Incidence Delayed Graft Function

    Time frame: Day 28

  7. Duration Delayed Graft Function

    Duration Delayed Graft Function

    Time frame: Day 28

  8. Incidence of Renal Replacement Therapy (RRT)

    Incidence of Renal Replacement Therapy (RRT)

    Time frame: Month 12

  9. Duration of Renal Replacement Therapy (RRT)

    Duration of Renal Replacement Therapy (RRT)

    Time frame: Month 12

  10. Incidence of New-Onset Diabetes after Transplantation (NODAT)

    Incidence of New-Onset Diabetes after Transplantation (NODAT)

    Time frame: Month 12

  11. Effect of Anti-Drug Antibody (ADA) Formation on VEL-101 t1/2 (hours)

    Effect of Anti-Drug Antibody (ADA) Formation on VEL-101 t1/2 (hours)

    Time frame: Months 1, 2, 3, 6, 9, 12 and Periprocedural (kidney biopsy)

  12. Effect of Anti-Drug Antibody (ADA) Development on VEL-101 Volume of distribution (liters)

    Effect of Anti-Drug Antibody (ADA) Development on VEL-101 Volume of distribution (liters)

    Time frame: Months 1, 2, 3, 6, 9, 12 and Periprocedural (kidney biopsy)

  13. Effect of Anti-Drug Antibody Development on VEL-101 Cmin (ng/mL)

    Effect of Anti-Drug Antibody Development on VEL-101 Cmin (ng/mL)

    Time frame: Months 1, 2, 3, 6, 9, 12 and Periprocedural (kidney biopsy)

  14. Effect of Anti-Drug Antibody Development on VEL-101 Cmax (ng/mL)

    Effect of Anti-Drug Antibody Development on VEL-101 Cmax (ng/mL)

    Time frame: Months 1, 2, 3, 6, 9, 12 and Periprocedural (kidney biopsy)

07

Study locations

1 of 1 sites recruiting
  • USA Site #1087
    Dallas, Texas 75390, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Oct 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 18, 2025
StartActual
Aug 18, 2026
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07290777
Lead sponsor
Veloxis Pharmaceuticals
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Aug 18, 2026
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Sep 3, 2026

Study contacts

Study Director
Contact
medinfo@veloxis.com
844-835-6947 or 1-984-309-4040

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegrizeprument

Start the discussion